Arrowhead Pharmaceuticals (ARWR) Intangibles (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Intangibles data on file, last reported at $6.0 million in Q1 2026.

• Quarterly Intangibles fell 22.05% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (down 22.05% YoY) and the FY2025 annual result came in at $6.9 million, down 19.87% from the prior year.
• Intangibles fell to $6.0 million in Q1 2026, from $6.4 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $12.8 million in Q1 2022 to a low of $6.0 million in Q1 2026.
• A 5-year average of $9.4 million and a median of $9.4 million in 2024 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2022 — Intangibles decreased 11.71% — and 2026, when it decreased 22.05%.
• Tracing ARWR's Intangibles over 5 years: stood at $11.5 million in 2022, then decreased by 14.74% to $9.8 million in 2023, then dropped by 17.28% to $8.1 million in 2024, then decreased by 20.9% to $6.4 million in 2025, then fell by 6.6% to $6.0 million in 2026.
• The last three Intangibles figures came in at $6.0 million (Q1 2026), $6.4 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.